RXST Stock Analysis: Rxsight | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 210m USD | 12M Return: -41.5% | Charts, Fundamentals & Technical Analysis

Adjustable Lenses, Cataract Surgery, Light Delivery, Vision Correction
Total Rating 22
Safety 81
Buy Signal -1.39
Medical Devices
Industry Rotation: +0.0
Market Cap: 210M
Avg Turnover: 6.71M
Risk 3d forecast
Volatility62.5%
VaR 5th Pctl10.4%
VaR vs Median1.05%
Reward TTM
Sharpe Ratio-0.56
Rel. Str. IBD1.8
Rel. Str. Peer Group6.5
Character TTM
Beta0.715
Beta Downside1.380
Hurst Exponent0.528
Drawdowns 3y
Max DD92.86%
CAGR/Max DD-0.50
CAGR/Mean DD-0.97
EPS (Earnings per Share) EPS (Earnings per Share) of RXST over the last years for every Quarter: "2021-06": -0.51, "2021-09": -0.68, "2021-12": -0.58, "2022-03": -0.64, "2022-06": -0.61, "2022-09": -0.61, "2022-12": -0.56, "2023-03": -0.31, "2023-06": -0.28, "2023-09": -0.19, "2023-12": -0.26, "2024-03": -0.12, "2024-06": -0.16, "2024-09": -0.16, "2024-12": 0.03, "2025-03": -0.03, "2025-06": -0.29, "2025-09": -0.24, "2025-12": -0.03, "2026-03": -0.19,
Last SUE: -0.30
Qual. Beats: 0
Revenue Revenue of RXST over the last years for every Quarter: 2021-06: 4.897, 2021-09: 5.786, 2021-12: 8.426, 2022-03: 8.942, 2022-06: 11.36, 2022-09: 12.615, 2022-12: 16.088, 2023-03: 17.489, 2023-06: 20.81, 2023-09: 30.667, 2023-12: 28.58, 2024-03: 29.512, 2024-06: 34.887, 2024-09: 45.408, 2024-12: 40.214, 2025-03: 37.895, 2025-06: 33.637, 2025-09: 30.34, 2025-12: 32.607, 2026-03: 30.893,
Rev. CAGR: 25.88%
Rev. Trend: 78.2%
Last SUE: 0.33
Qual. Beats: 0

Warnings

High Debt While Negative Cash Flow
Interest Coverage Ratio Critical
Fakeout
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 4.9 years of data

Jan -1.3% 19
Feb -3.7% 22
Mar -6.9% 23
Apr -4.2% 0
May +6.8% 0
Jun -0.6% 0
Jul -9.9% 0
Aug -0.5% 0
Sep -5.3% 21
Oct -1.1% 0
Nov +11.7% 0
Dec -2.5% 19

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RXST Rxsight

RxSight, Inc. (NASDAQ: RXST) is a U.S.-based, commercial-stage medical technology company that develops, manufactures, and sells the RxSight System, which is used in cataract surgery. The system consists of two main components: the Light Adjustable Lens (LAL), a photosensitive intraocular lens implanted in the eye, and a light delivery device that emits targeted UV light to non-invasively reshape the lens after surgery, allowing ophthalmologists to fine-tune the patients visual acuity post-procedure.

The company follows a hybrid business model, selling capital equipment (the light delivery device) to ophthalmologists while generating recurring revenue from the sale of the adjustable lenses as single-use consumables per procedure. Cataract surgery is one of the most frequently performed surgical procedures in the world, and the premium intraocular lens segment that RxSight targets represents a differentiated, higher-margin niche within the broader ophthalmology market. Headquartered in Aliso Viejo, California, the company was originally incorporated in 1997 as Calhoun Vision before adopting the RxSight name in February 2017. It trades on NASDAQ as a micro-cap stock following its July 2021 IPO.

Headlines to Watch Out For
  • LAL procedure volume growth drives quarterly revenue beat
  • Gross margin expansion accelerates path to profitability
  • Competition from premium intraocular lens makers intensifies
Piotroski VR-10 (Strict) 1.0
Net Income: -46.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA -0.55 > 1.0
NWC/Revenue: 197.6% < 20% (prev 167.7%; Δ 29.85% < -1%)
CFO/TA -0.06 > 3% & CFO -17.6m > Net Income -46.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.20 > 1.5 & < 3
Outstanding Shares: last quarter (41.3m) vs 12m ago 1.97% < -2%
Gross Margin: 77.02% > 18% (prev 67.29%; Δ 9.73% > 0.5%)
Asset Turnover: 41.32% > 50% (prev 50.60%; Δ -9.28% > 0%)
Interest Coverage Ratio: -2.74k > 6 (EBIT TTM -46.6m / Interest Expense TTM 17.0k)
Altman Z'' 4.81
A: 0.83 (Total Current Assets 279.2m - Total Current Liabilities 27.4m) / Total Assets 304.0m
B: -2.23 (Retained Earnings -676.9m / Total Assets 304.0m)
C: -0.15 (EBIT TTM -46.6m / Avg Total Assets 308.5m)
D: 7.28 (Book Value of Equity 267.3m / Total Liabilities 36.7m)
Altman-Z'' = 4.81 = AA
Beneish M -3.02
DSRI: 0.90 (Receivables 22.4m/31.0m, Revenue 127.5m/158.4m)
GMI: 0.87 (GM 67.29% / 77.02%)
AQI: 1.59 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 0.80 (Revenue 127.5m / 158.4m)
TATA: -0.10 (NI -46.6m - CFO -17.6m) / TA 304.0m)
Beneish M = -3.02 (Cap -4..+1) = AA
What is the price of RXST shares?

As of July 11, 2026, the stock is trading at USD 4.95 with a total of 690,451 shares traded. Over the past week, the price has changed by -11.76%, over one month by +7.61%, over three months by -27.53% and over the past year by -41.49%.

Current recommended Stop Loss: 4.30 (which is 13.1% or 1.6 ATR below the current price).

Is RXST a buy, sell or hold?

Rxsight has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold RXST.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 3
  • Sell: 2
  • StrongSell: 0

What are the forecasts/targets for the RXST price?
Analysts Target Price 8.4 70.3%
Rxsight (RXST) - Fundamental Data Overview as of 11 July 2026
Market Cap USD = 210.3m (210.3m USD * 1.0 USD.USD)
P/E Forward = 116.2791
P/S = 1.6497
P/B = 0.8278
Revenue TTM = 127.5m USD
EBIT TTM = -46.6m USD
EBITDA TTM = -43.2m USD
Long Term Debt = 9.32m USD (estimated: total debt 10.8m - short term 1.50m)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (from shortLongTermDebtTotal, last quarter) (leases 10.8m already included)
Net Debt = -207.1m USD (calculated: Debt 10.8m - CCE 217.9m)
Enterprise Value = 3.24m USD (210.3m + Debt 10.8m - CCE 217.9m)
Interest Coverage Ratio = -2.74k (Ebit TTM -46.6m / Interest Expense TTM 17.0k)
EV/FCF = -0.15x (Enterprise Value 3.24m / FCF TTM -21.6m)
 FCF Yield = -666.0% (FCF TTM -21.6m / Enterprise Value 3.24m)
 FCF Margin = -16.93% (FCF TTM -21.6m / Revenue TTM 127.5m)
Net Margin = -36.58% (Net Income TTM -46.6m / Revenue TTM 127.5m)
Gross Margin = 77.02% ((Revenue TTM 127.5m - Cost of Revenue TTM 29.3m) / Revenue TTM)
Gross Margin QoQ = 76.06% (prev 77.48%)
Tobins Q-Ratio = 0.01 (Enterprise Value 3.24m / Total Assets 304.0m)
Interest Expense / Debt = 0.16% (Interest Expense 17.0k / Debt 10.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.8m (EBIT -46.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.20 (Total Current Assets 279.2m / Total Current Liabilities 27.4m)
Debt / Equity = 0.04 (Debt 10.8m / totalStockholderEquity, last quarter 267.3m)
 Debt / EBITDA = 4.79 (negative EBITDA) (Net Debt -207.1m / EBITDA -43.2m)
 Debt / FCF = 9.59 (negative FCF - burning cash) (Net Debt -207.1m / FCF TTM -21.6m)
 Total Stockholder Equity = 274.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.12% (Net Income -46.6m / Total Assets 304.0m)
RoE = -17.01% (Net Income TTM -46.6m / Total Stockholder Equity 274.2m)
RoCE = -16.42% (EBIT -46.6m / Capital Employed (Equity 274.2m + L.T.Debt 9.32m))
 RoIC = -13.54% (negative operating profit) (NOPAT -36.8m / Invested Capital 271.7m)
 WACC = 8.09% (E(210.3m)/V(221.1m) * Re(8.50%) + D(10.8m)/V(221.1m) * Rd(0.16%) * (1-Tc(0.21)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 6.35%
 [DCF] Fair Price = unknown (Cash Flow -21.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.30 | # QB: 0
Revenue Correlation: 78.17 | Revenue CAGR: 25.88% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=-17.65% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+4.29% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.70 | Chg30d=-8.53% | Revisions=-25% | GrowthEPS=-288.9% | GrowthRev=+1.9%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=-16.06% | Revisions=-25% | GrowthEPS=+20.0% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: -12% (up=2, down=3)